[Market Focus] Genematrix Shares Surge on News of U.S. Patent Registration

As of 9:10 a.m. on September 17, the share price of Genematrix was up 29.94%-the daily price limit-at 3,190 won compared to the previous closing price. This surge appears to be due to the company's announcement that its cervical cancer therapeutic vaccine candidate, GMPV-12, has been registered as a U.S. patent.

Genematrix stated, "With this patent registration, we have secured exclusive rights to our artificial intelligence (AI)-based antigen redesign core technology, establishing a crucial foundation for entering the global market."

GMPV-12 is a therapeutic agent that uses AI-based protein modeling techniques to redesign the antigen of high-risk human papillomavirus (HPV). It works by activating immune cells known as T cells within the body to treat cancer. Its efficacy has been validated in a cervical cancer animal model by a research team at Johns Hopkins University in the United States.

The company reported that in the efficacy experiment, the group treated with GMPV-12 showed effective suppression of tumor growth, and the T cell immune response that destroys cancer tissue was three times higher compared to the control group.

Genematrix is preparing for clinical trials of GMPV-12 following the U.S. patent registration and also plans to pursue joint development and technology transfer partnerships with global pharmaceutical companies.

This content was produced with the assistance of AI translation services.